seeks to obtain financing to recruit a CEO and pursue commercialization through contracted development, partnering and out-licensing of 1) its gene-based prostate cancer testing technology and 2) its cancer metastasis prevention and treatment technology. It has filed and is prosecuting patents covering its technologies in the US and major countries around the world, and also maintains its gene signature test details as trade secrets.